Veliflapon BAY X 1005; DG-031|cas:128253-31-6|西域试剂

Veliflapon BAY X 1005; DG-031,99.48%

产品编号：Bellancom-14165| CAS NO：128253-31-6| 分子式：C₂₃H₂₃NO₃| 分子量：361.43

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-14165	￥2500.00	杭州北京（现货）
Bellancom-14165	￥4000.00	杭州北京（现货）
Bellancom-14165	￥8000.00	杭州北京（现货）
Bellancom-14165	￥12800.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Veliflapon BAY X 1005; DG-031

产品介绍

Veliflapon (BAY X 1005; DG-031) 是一种具有口服活性的，选择性的 5-脂氧合酶激活蛋白 (FLAP) 抑制剂。Veliflapon 也是白三烯 B4 和 C4 合成的抑制剂。

生物活性

Veliflapon (BAY X 1005; DG-031) is an orally active and selective 5-lipoxygenase activating protein (FLAP) inhibitor. Veliflapon inhibits the synthesis of the leukotrienes B4 and C4.

体外研究

Veliflapon (BAY X 1005; DG-031) effectively inhibits the synthesis of LTB4 in A23187-stimulated leukocytes from rats, mice and humans (IC₅₀s of 0.026, 0.039 and 0.22 μM, respectively) as well as the formation of LTC4 (IC₅₀ of 0.021 μM) in mouse peritoneal macrophages stimulated with opsonized zymosan.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Veliflapon (BAY X 1005; DG-031; diet; 18.8 mg/kg/day for 16 weeks ) inhibits atherogenesis^[4].
Veliflapon after topical (18 μg/ear) and oral (48.7 mg/kg) administration has antiedematous effects in the arachidonic acid-induced mouse ear inflammation test^[4].
Veliflapon is potent (11.8 and 6.7 mg/kg p.o. at 1 and 5 hours, respectively) and has a long duration of action (ED₄₀ of 16 hours, 70 mg/kg p.o.) in the rat whole blood ex vivo leukotriene B4 inhibition assay^[4].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female apoE/LDLR-DKO mouse model^[4]
Dosage:	18.8 mg/kg
Administration:	Diet; per day during 16 weeks
Result:	Inhibited atherogenesis.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female apoE/LDLR-DKO mouse model^[4]
Dosage:	18.8 mg/kg
Administration:	Diet; per day during 16 weeks
Result:	Inhibited atherogenesis.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (276.68 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.7668 mL	13.8339 mL	27.6679 mL
5 mM	0.5534 mL	2.7668 mL	5.5336 mL
10 mM	0.2767 mL	1.3834 mL	2.7668 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式